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To provide an early estimate of 2011/12 influenza vac-
cine effectiveness (VE), we conducted a multicentre 
case–control study based on seven sentinel surveil-
lance networks. We included influenza-like illness 
cases up to week 7/2012 from the vaccination target 
groups, swabbed less than eight days after symptom 
onset. Laboratory-confirmed influenza A(H3) cases 
were compared to negative controls. Adjusted VE was 
43% (95% confidence interval: -0.4 to 67.7), suggest-
ing low to moderate VE against influenza A(H3) in the 
early 2011/12 season. 
Introduction 
In the context of the Influenza Monitoring Vaccine 
Effectiveness in Europe (I-MOVE) Network we esti-
mated the effectiveness of the 2011/12 trivalent vaccine 
against medically attended influenza-like illness (ILI) 
that was laboratory-confirmed as influenza. We under-
took a multicentre case–control study based on the 
European Influenza Sentinel Practitioner Surveillance 
Networks (EISN) [1] from eight study sites (France, 
Hungary, Ireland, Italy, Poland, Portugal, Romania and 
Spain).
Data were collected from week 48/2011 to week 7/2012. 
During these 12 weeks of data collection, 867 (92.7%) 
of 935 laboratory-confirmed influenza cases recruited 
in the study were identified as influenza A(H3). This 
finding was consistent with data from the Community 
Network of Reference Laboratories (CNRL) for Human 
Influenza in Europe: of the 11,159 viruses detected from 
week 40/2011 to week 7/2012, 95.9% were influenza 
type A, and of 6,238 influenza A viruses subtyped, 
97.5% were influenza A(H3) [2].
We provide early season estimates of the effective-
ness of the 2011/12 vaccine against influenza A(H3) 
virus among those subpopulations identified as tar-
get groups for vaccination in the respective countries 
(Table 1) [3-10].
Methods
The study population consisted of non-institutionalised 
patients of all ages (over the age of 17 years in Hungary) 
consulting a participating practitioner for ILI and hav-
ing a naso-pharyngeal swab taken less than eight days 
after symptom onset. Recruitment of ILI patients was 
based on exhaustive (Romania), systematic (Hungary, 
Ireland, Italy, Poland, Portugal, Spain) or quota sam-
pling (France) [11]. The European Union case definition 
for ILI was used: sudden onset of symptoms, at least 
one of these four systemic symptoms (fever or feverish-
ness, malaise, headache, myalgia) and at least one of 
these three respiratory symptoms (cough, sore throat, 
shortness of breath) [12]. A case of confirmed influenza 
A(H3) was an ILI patient who was swabbed and tested 
positive for influenza A(H3) virus using RT- PCR or cul-
ture. Controls were ILI patients who tested negative for 
any influenza virus.
Individuals were considered vaccinated if they had 
received a dose of the 2011/12 seasonal vaccine more 
than 14 days before the date of onset of ILI symptoms, 
and unvaccinated if they had received no vaccine or 
the vaccine was given less than 15 days before the 
onset of ILI symptoms. The variables collected during 
this season were the same as in 2010/11 [13], except 
for pandemic vaccination (not collected in 2011/12) 
and smoking (not collected in France). In each country 
we included ILI patients who presented to the practi-
tioner up to the end of week 7/2012 who belonged to 
a target group for vaccination, with onset of symptoms 
more than 14 days after the start of national or regional 
influenza vaccination campaigns. For each study site, 
we excluded controls with symptom onset in the weeks 
before symptom onset of the first influenza A(H3) case, 
as well as cases infected with any non-A(H3) influenza 
virus.
We conducted a complete case analysis excluding indi-
viduals with missing values. We estimated the pooled 
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Table 1
Target groups for influenza vaccination in eight European Union countries, influenza season 2011/12
Country Target groups for vaccination
Fr
an
ce
•	 People aged 65 years and older
•	 >6 months with chronic conditions (chronic respiratory disease, chronic respiratory failure, bronchopulmonary dysplasia, 
cystic fibrosis, chronic cardiac failure, cardiovascular disease, diabetes type 1 and type 2, severe neurological and muscular 
disease, chronic renal disease, body mass index >30)
•	 Pregnant women in second and third trimester
•	 Residents of long-term care facilities
•	 Healthcare workers
•	 Carers in direct contact with at-risk patients
•	 Household contacts of at-risk children under the age of 6 months 
•	 Personnel working on cruise ships or planes, and tour guides
Hu
ng
ar
y
•	 People aged 65 years and older
•	 >6 months with chronic conditions (respiratory illness, body mass index ≥35, neuromuscular disease, cardiovascular disease 
except well treated hypertension, congenital or acquired immundeficiency including HIV infection and cancer,chronic hepatic 
or renal disease, chronic metabolic disease including diabetes)
•	 Pregnant women or women planning to be pregnant during the influenza season
•	 Healthcare and social workers
Ire
la
nd
•	 People aged 65 years and older
•	 >6 months with chronic conditions (chronic respiratory disease, chronic heart disease, neurological disease, diabetes 
mellitus, liver disease, neurological disease including sclerosis, hereditary and degenerative disorders of the central 
nervous system, body mass index ≥40, immunosuppression due to disease or treatment including those with missing or non-
functioning spleen)
•	 Pregnant women (any stage and up to 6 weeks post partum)
•	 Children with any condition that can compromise respiratory function, especially those attending special schools/day centres
•	 Children and teenagers on long-term aspirin therapy (risk of Reyes syndrome)
•	 Residents of nursing homes and other long-stay institutions
•	 Carers in direct contact with at-risk patients
•	 People in close, regular contact with pigs, poultry or water fowl
•	 Healthcare workers
Ita
ly
•	 People aged 65 years and older
•	 >6 months with chronic conditions (chronic respiratory disease, chronic cardiovascular disease, neurological disease, 
diabetes mellitus and metabolic diseases including obesity with body mass index >30, liver disease, renal disease, 
immunosuppression and HIV infection, chronic inflammatory diseases, tumours, pathologies of the hematopoyetic 
organs, pathologies for which an important chirurgical intervention is planned, pathologies producing an increased risk of 
respiratory aspirations
•	 Pregnant women in second and third pregnancy trimester
•	 People working in essential public services 
•	 People working with animals that could be infected with influenza 
•	 Residents of nursing homes and long-term care facilities
•	 Household contacts of at-risk persons
•	 Healthcare workers
•	 Children with long-term salicylate therapy
Po
la
nd
•	 People aged 55 years and older
•	 > 6 months with chronic condition (asthma, diabetes, cardiovascular or respiratory disease, renal failure, hepatic disease, 
neurological disease, congenital or acquired immundeficiency, organ transplantion, body mass index ≥40)
•	 Healthcare, school, trade and transport workers and other staff exposed to large numbers of people
•	 Healthy children between 6 months and 18 years of age
Po
rt
ug
al
•	 People aged 65 years and older (but also recommended to those over the age of 60 years)
•	 >6 months with chronic conditions (chronic respiratory disease, cardiovascular disease, metabolic disorders, renal or hepatic 
disease, congenital or acquired immunodeficiency, chronic neurological or neuromuscular disorders, any other condition 
impairing immunity or respiratory function, body mass index ≥ 30)
•	 Pregnant women in second trimester
•	 Household contacts and carers of children under the age of 6 months with high risk of developing complications
•	 Health professionals, care givers in nursing homes and domiciliary service
Ro
m
an
ia
•	 People aged 65 years and older
•	 >6 months with chronic conditions (respiratory, cardiovascular, renal or hepatic diseases, diabetes, metabolic disorders, HIV 
infection, obesity
•	 Pregnant women
•	 Persons institutionalised for social care
•	 Healthcare workers
Sp
ai
n
•	 People aged 59 years and older or 64 years and older, depending on the region
•	 >6 months with chronic conditions (diabetes, cardiovascular, lung, kidney or hepatic diseases, immunodeficiency, body mass 
index ≥40) 
•	 Pregnant women
•	 Children <15 years under salicylate therapy
•	 Healthcare workers, people in contact with high-risk groups, essential civil servants, people in contact with birds
HIV: human immunodeficiency virus.
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seasonal influenza vaccine effectiveness (VE) as 1 
minus the odds ratio (OR) expressed as a percentage, 
using a one-stage method with the study site as fixed 
effect in the model.
To estimate adjusted VE, we used logistic regression 
models including the following potential confounding 
factors: age groups (10-year age bands), sex, week of 
symptom onset, chronic disease (at least one), hos-
pitalisations associated with a chronic disease in the 
last 12 months, and number of visits to a general prac-
titioner or paediatrician in the last 12 months.
Results
Among the 1,056 practitioners who agreed to par-
ticipate, 528 (50%) recruited at least one ILI case 
(Table 2).
Of the 2,090 ILI cases recruited, 575 belonged to a tar-
get group for vaccination. After excluding the weeks 
before symptom onset of the first influenza A(H3) 
case at each of the study sites and 10 cases positive 
for other influenza viruses, we included 208 influ-
enza A(H3) cases and 330 influenza-negative controls 
(Figure). Poland is not included in this preliminary anal-
ysis as no influenza A(H3) case was detected.
The first study site to recruit an influenza A(H3) case 
in the target group for vaccination was Italy (week 
48/2011), and the last sites were France, Romania and 
Spain (week 52/2011) (Table 2). The median number of 
weeks during which patients were recruited for the pre-
liminary analysis was nine, ranging from six in France 
to 12 in Italy (Table 2).
Differences in the characteristics of influenza A(H3) 
cases and controls are presented in Table 3.
Among 533 individuals for whom vaccination sta-
tus was available, 179 (33.5%) were vaccinated. The 
median time since vaccination was 105 and 74 days for 
cases and controls, respectively (p=0.031).
The complete case analysis was done for 530 individu-
als after excluding those with missing information on 
2011/12 seasonal vaccination (n=5), on hospitalisa-
tions for chronic disease in the previous year (n=2) and 
on practitioners’ visits in the previous year (n=1). The 
crude VE against influenza A(H3) was 42.9 (95% confi-
dence interval (CI): 10.3 to 63.6) and the adjusted 43% 
(95% CI: -0.4 to 67.7) (Table 4).
Discussion
Our pooled early estimates suggest that the point esti-
mate of the of the 2011/12 influenza vaccine against 
influenza A(H3) in the target group for vaccination was 
below 50%. These results are consistent with the VE 
against influenza A(H3) estimated in Australia for the 
season 2011 (58%, 95% CI: -53 to 89) [14] and with 
the Spanish early estimates of the 2011/12 VE against 
influenza A(H3) among target group for vaccination 
(54%, 95% CI: 1 to 79) [15].
Table 2
Participating practitioners and recruited influenza-like illness patients, by A(H3) influenza case-control status, vaccination 
status and study site, multicentre case-control study, study sites in eight European Union countries,  
week 48/2011–week 7/2012
Study 
site
Number of 
practitioners 
participating 
in the study 
Number of 
practitioners 
recruiting at 
least one  
ILI patienta
Number of 
ILI patientsa  
recruited by 
practitioners
Inclusion period for the  
preliminary analysis  
(ISO weeks)b
Number of included ILI 
patients positive for 
influenza A(H3) and 
with known vaccination 
statusc
Number of included ILI 
patients negative for any 
influenza and with known 
vaccination statusc
Total Vaccinated Total Vaccinated
France 499 169 325 Week 52/2011–week 6/2012 4 1 24 12
Hungary 94 63 354 Week 49/2011–week 7/2012 2 0 112 41
Ireland 28 11 60 Week 50/2011–week 7/ 2012 5 4 3 3
Italy 10 10 143 Week 48/2011–week 7/2012 18 6 33 15
Poland 35 15 45
Not included in preliminary 
analysis (no influenza A(H3) 
cases)
0
Portugal 59 30 149 Week 51/2011–week 7/2012 23 5 47 24
Romania 100 56 128 Week 52/2011–week 7/2012 18 1 31 6
Spain 231 174 886 Week 52/2011–week 7/2012 136 37 77 24
Total 1,056 528 2,090 206 54 327 125
ILI: influenza-like illness; ISO: International Organization for Standardization. 
a ILI patients meeting the European Union case definition, swabbed less than eight days after onset of symptoms within the study period.
b From 15 days after the start of the vaccination campaign to week 7/2012; we excluded controls with an onset of symptoms in the weeks 
before the first influenza A(H3) case in the study site.
c ILI patients in a vaccination target group included in the study, after excluding those with missing information on laboratory results, 
vaccination status or date of vaccination.
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The late start of the 2011/12 season in Europe [2] and 
the low influenza incidence in some of the eight coun-
tries participating in the multicentre case–control 
season limited the sample size for this preliminary 
analysis. By week 7/2012, four of the eight countries 
participating in the study had not reached the peak of 
the influenza season.
We included ILI patients swabbed less than eight days 
after symptom onset. Due to the small sample size 
we did not assess potential misclassification (false 
influenza A(H3)-negatives because of late swabbing) 
by restricting the analysis to those swabbed less 
than four days after ILI onset. However, only 12% of 
the ILI patients included in this preliminary analysis 
were swabbed more than three days after onset of ILI 
symptoms (Table 2). This will be addressed in the final 
analysis.
There were important differences between target 
groups for vaccination and non-target groups (data not 
shown). The vaccine coverage was 2.8% in the non-tar-
get groups compared to 33.8% in the target groups and 
the median age was 26 years and 56 years respectively. 
In this preliminary analysis our results are restricted to 
the population for which the vaccine is recommended.
We collected information on the main potential con-
founding factors described in the literature [16]. The 
crude and adjusted VE were similar, suggesting that 
within this subpopulation and using a specific labora-
tory-confirmed outcome, the presence of known con-
founding was minimised.
The low to moderate VE we observed may be explained 
by a limited match identified between the circulating 
influenza A(H3) virus strains and the vaccine strain [2]. 
In February 2012, the vaccine strain selection commit-
tee at the World Health Organization (WHO) concluded 
that there was evidence of increasing antigenic and 
genetic drift in circulating influenza A(H3N2) and con-
sequently recommended to include a different influ-
enza A(H3) vaccine strain in the 2012/13 seasonal 
vaccine [17].
In the 2011/12 season, the time lag between the begin-
ning of the vaccination campaigns and the start of the 
influenza season was longer than in previous seasons. 
In our preliminary analysis, the delay from vaccination 
to onset of symptoms was longer in cases than in con-
trols. This may suggest that waning immunity has con-
tributed to the moderate VE observed. However, with 
the sample available for this preliminary analysis, we 
could not verify this hypothesis.
Our preliminary estimates suggest that, among the 
target groups for vaccination, the effectiveness of the 
2011/12 influenza vaccine is low to moderate against 
medically-attended ILI confirmed as influenza A(H3). At 
the end of the season, a larger sample size per study 
site may allow us to estimate also the VE against other 
influenza viruses, by age group, and to further explore 
hypotheses on the reasons for the low VE observed 
early in the season.
Figure 
Influenza A(H3) cases (n=208) and influenza-negative controls (n=330) in vaccination target groups recruited at study sites in 
seven European Union countries, by week of symptom onset, week 48/2011–week 7/2012
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International Organization for Standardization (ISO) definition of a week. 
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Characteristic Number of influenza cases/total n (%)a
Number of test-negative 
controls/total n (%)a P value
Median age 56.0 56.0 1.000b
Age group (years)
0-4 
5-14
15-64
≥65
6/208 (2.9)
17/208 (8.2)
115/208 (55.3)
70/208 (33.7)
13/330 (4.0)
10/330 (3.2)
201/330 (61.0)
106/330 (32.1)
0.050c
Females 117/208 (56.3) 208/330 (53.6) 0.124c
Symptoms 
Fever
Malaise
Headache
Myalgia
198/206 (96.1)
194/202 (96.0)
179/207 (86.5)
185/207 (89.4)
293/320 (89.1.7)
277/304 (91.1)
243/327 (74.3)
258/327 (78.9)
0.003c
0.033c
0.001c
0.002c
Days between onset of symptoms and swabbing
0
1
2
3
≥4
8/208 (3.9)
74/208 (35.6)
63/208 (30.3)
44/208 (21.2)
19/208 (9.1)
21/330 (6.4)
113/330 (34.2)
100/330 (30.3)
48/330 (14.6)
48/330 (14.6)
0.101c
Seasonal influenza vaccinationd, 2011/12 54/206 (26.2) 125/327 (38.2) 0.005c
Seasonal influenza vaccination, 2010/11 50/206 (24.3) 126/323 (39.0) <0.001c
Obese 21/207 (10.1) 57/330 (17.3) 0.024c
Heart diseases 36/208 (17.3) 107/330 (32.4) <0.001c
At least one chronic disease 121/208 (58.2) 254/330 (77.0) <0.001c
Smoker 
Current
Former
Never
30/202 (14.9)
22/202 (10.9)
150/202 (74.3)
49/302(16.2)
53/302(17.5)
200/302(66.2)
0.087c
Median number of practitioners’ visits  
in the previous 12 months 4 5 0.031
b
Any hospitalisation in the previous 12 
months for chronic diseases 9/208 (4.3) 23/327 (7.0) 0.262
c
Median number of days from vaccinationd  
to onset of ILI symptoms 105 74 <0.001
b
ILI: influenza-like illness.
a Unless otherwise indicated.
b Non-parametric test of the median.
c Two-sided Fisher’s exact test.
d Vaccination more than 14 days before onset of ILI symptoms.
Table 3
Characteristics of A(H3) influenza cases (n=208) and test-negative controls (n=330) in vaccination target groups included 
from study sites in seven European Union countries, week 48/2011–week 7/2012
Crude versus adjusted Cases/controls Vaccinated cases/controls Vaccine effectiveness (%) 95% confidence intervals
Crudea 206/324 54/123 42.9 10.3 to 63.6
Adjusted model b, c 43.0 -0.4 to 67.7
a  Study site included in the model as fixed effect.
b  Model adjusted for presence of at least one chronic disease, sex, at least one hospitalisation for chronic disease in the previous 12 months, 
age group, practitioners’ visits in the previous 12 months ( 0-1, 2-4 and ≥5 visits) and week of symptom onset.
c  Onset week 49 dropped due to no cases (nine records dropped).
Table 4
Pooled crude (n=530) and adjusted (n=521) 2011/12 seasonal influenza vaccine effectiveness against laboratory-confirmed 
A(H3) influenza in target groups for vaccination at study sites in seven European Union countries, week 48/2011–week 7/2012
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